Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

May 17, 2025
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

1
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

2
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

3
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

4
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

5
September 22, 2023October 1, 2023

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

6

Search Field

Subscribe Now

  • Home
  • FEATURED
  • COVID UPDATE: COVID elixir by Oxford is unsafe? Trials put on hold yet again!

Calcium channels prohibit pathogen entry

Molecules for Life- Thioredoxin System

COVID UPDATE: COVID elixir by Oxford is unsafe? Trials put on hold yet again!
  • BiotechToday
  • FEATURED
  • Latest
  • World

COVID UPDATE: COVID elixir by Oxford is unsafe? Trials put on hold yet again!

bioxone September 9, 2020September 9, 2020

-Binayak Das, Team bioXone

The highly-awaited trials for the Covid-19 vaccine formulation by Oxford have yet again been put on hold for a second time this year. The reason behind this has to do with certain safety concerns, as informed to Stat News, on Tuesday. This measure was taken by AstraZeneca Plc. right after they observed potentially hazardous reaction-response, in a trial participant. A statement coming directly from AstraZeneca Plc personnel stated that their standard review process instigated a pause to vaccination, so as to allow the review of their safety data. 
The details about what the safety issue is exactly have not yet been made public by neither AstraZeneca nor by the researchers at the University of Oxford, although they mentioned that the patient is not in critical condition and will supposedly, recover soon, according to Stat News.

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X

Related

Tagged CORONA VACCINE Covid Oxford VACCINE VACCINE IN INDIA

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • DNA-Tales
  • FEATURED
  • Latest
  • Scientists' Corner

Molecules for Life- Thioredoxin System

bioxone September 9, 2020

–Esha Sircar & Dr. Rajib Sengupta, Amity Institute of Biotechnology, Amity University Kolkata The thioredoxin (Trx) system is a major antioxidant system that maintains the intracellular redox state. It contains Trx, a redox-active protein, which regulates the activity of various enzymes including those that function to counteract oxidative stress within the cell. Trx, NADPH, and […]

Related Post

  • BiotechToday
  • World

Drug amount regulation by implanted SMART

bioxone September 5, 2021September 5, 2021

Nandini Pharasi, Jaypee Institute of Information Technology When implanted in mice, the gene-modified cells will produce a biological medicine that can cure inflammation, allowing the researchers in St. Louis to create therapies for rheumatoid arthritis that have minimal adverse effects. Rheumatoid arthritis, a severe illness that affects about 1.3 million individuals in the United States, […]

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • BiotechToday
  • World

Phylloid-type pigmentary | mosaicism and ambiguous genitalia | trisomy 14 | der(Y)t(Y;14)

bioxone September 30, 2020September 30, 2020

-Husna, Amity University Kolkata Trisomy 14 is an aneusomy that is viable with life if present in a mosaic individual. Mostly, the symptoms are prenatal and postnatal growth failure, genitourinary and ear abnormalities, congenital heart defects, developmental delay, narrow palpebral fissures, broad nose, short jaw, and short neck. A clinical survey on 51 patients showed […]

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • BiotechToday
  • World

Understanding the Nobel prize-winning discovery in chemistry

BioTech Today October 19, 2021October 19, 2021

Debarati Basu, Makaut WB Benjamin List of Germany and David W.C. MacMillan of the United States were honoured jointly with the Nobel Prize in Chemistry 2021. They were awarded for their development of asymmetric organocatalysis. Their findings were an environmentally safer, cleaner, cheaper, and more effective method to build molecules. This method is applicable in […]

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X

Breaking News

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Exogenous Klotho as a Cognition Booster in Aging Primates

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy